Skip to content
OpenCapital
Get started

Perspective Therapeutics CATX Enterprise value

Enterprise value at other companies

Eli Lilly logo
Eli LillyLLY
$859.77B+10.6%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$990.06M+8,530%
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
$314.35M+72.3%
Immunome logo
ImmunomeIMNM
$1.9B+470%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.86B+85.0%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$5.07B-20.5%

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%—

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0×0.0×
Current ratio8.7×-8.3×

Where this comes from

Calculated from Perspective Therapeutics’s reported figures.

$475.1Mmarket cap+$4.2Mtotal debt−$54.0Mcash and equivalents=$425.31M

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's enterprise value?
Perspective Therapeutics (CATX) reported enterprise value of $425.31M in Q1 2026.
How has Perspective Therapeutics's enterprise value changed year-over-year?
Perspective Therapeutics's enterprise value increased by 263.2% year-over-year, from $117.09M to $425.31M.
What is the long-term trend for Perspective Therapeutics's enterprise value?
Over 4 years (2020 to 2025), Perspective Therapeutics's enterprise value has grown at a 57.6% compound annual growth rate (CAGR), from $28.68M to $177M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.